9/17
06:02 pm
avbp
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
Low
Report
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
9/11
12:19 pm
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.
9/10
12:10 pm
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $39.00 price target on the stock, up previously from $35.00.
9/10
10:04 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $38.00. They now have a "buy" rating on the stock.
9/10
08:01 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $30.00 to $36.00. They now have a "buy" rating on the stock.
9/9
12:09 pm
avbp
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer [Yahoo! Finance]
Medium
Report
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer [Yahoo! Finance]
9/9
12:05 pm
avbp
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
Medium
Report
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
9/6
08:22 am
avbp
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate [Yahoo! Finance]
8/19
11:39 am
avbp
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet [Yahoo! Finance]
8/19
10:40 am
avbp
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength [Yahoo! Finance]
Low
Report
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength [Yahoo! Finance]
8/16
08:12 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
8/15
11:19 pm
avbp
Alphamab Oncology Reports 2024 Interim Results and Business Highlights [Yahoo! Finance]
Low
Report
Alphamab Oncology Reports 2024 Interim Results and Business Highlights [Yahoo! Finance]
8/15
10:30 am
avbp
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $35.00 price target on the stock.
Low
Report
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $35.00 price target on the stock.
8/15
07:10 am
avbp
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma [Yahoo! Finance]
Low
Report
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma [Yahoo! Finance]
8/14
04:19 pm
avbp
ArriVent BioPharma Reports Second Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Second Quarter 2024 Financial Results [Yahoo! Finance]
8/14
04:01 pm
avbp
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
Low
Report
ArriVent BioPharma Reports Second Quarter 2024 Financial Results